Good morning, everyone, and welcome to the working week. We hope the weekend was relaxing and filled with all sorts of fun. Now, though, that familiar routine of meetings and deadlines is resuming. And for us that can mean just one thing - a needed cup of stimulation. So please join us as we fortify ourselves for a busy day. There is, after all, much to do, especially with various upcoming conferences. Meanwhile, here are some tidbits to help you get started. Have a great day and let us know if you hear anything interesting...
FDA Approves New Breast Cancer Drug From Roche (Xconomy)
FDA Delays Decision On Gilead Pill For HIV Prevention (Associated Press)
Roche Will Not Revisit Illumina Bid (Reuters)
Merck Serono Workers Mull Strike Action (World Radio Switzerland)
J&J Diabetes Drug Tops Older Meds In Study (Reuters)
Sanofi's Lantus Cut Blood Sugar More Than Merck's Januvia (Wall Street Journal)
Amgen's Sensipar Fails In Late-Stage Trial (Pharma Times)
Sanofi Slashes Its Number Of Data Centers (Computerworld)
Indian Drugmakers Complain About Cost-Based Pricing (Economic Times)
EDITOR'S NOTE: Please check this post for updates during the day
steaming coffee pic thx to dleggett on flickr
3 Comments
German regulator for reimbursement (added-value evaluation of new meds) is now starting to probe even older compounds for their addition value to the patient.
After a negative assessment for linagliptin in March 2012
http://www.g-ba.de/downloads/40-268-1919/2012-03-29_AM-RL-XII_Linagliptin_ZD.pdf
it now started an assessment procedure for all gliptins
http://www.g-ba.de/downloads/39-261-1499/2012-06-07_35a_Bestandsmarkt.pdf
...and the party will go on.